Tocilizumab (Actemra)

Actemra (tocilizumab) is covered for FDA‑approved non‑oncology indications — adult moderately‑to‑severely active rheumatoid arthritis, adult giant cell arteritis, and polyarticular and systemic juvenile idiopathic arthritis in patients ≥2 years — and is not permitted with concurrent biologic agents or for non‑approved off‑label compendial uses. Approval (up to 12 months) requires no active infection, latent TB screening and treatment if positive, documentation of the FDA‑listed diagnosis and specified prior treatment failures or contraindications (e.g., methotrexate/other DMARDs or TNF‑inhibitors as indicated), appropriate weight/age dosing, and reauthorization requires evidence of improvement or stability.

"Actemra is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic ..."